# Point-of-care Nucleic Acid Amplification Test for pangenomic Hepatitis C diagnosis in outpatient clinics

> **NIH NIH R01** · UNIVERSITY OF WASHINGTON · 2024 · $776,510

## Abstract

ABSTRACT
Hepatitis C virus (HCV) infection is a widely prevalent bloodborne infection, with approximately 71 million global
(2.4 million in USA) chronic infections worldwide. HCV infection is frequently asymptomatic and many of those
infected are unaware of their illness. Untreated HCV infection may lead to chronic liver disease, such as
hepatocellular carcinoma, and accounts for an estimated 1.1 million annual global deaths (14,000 USA). Within
the last six years, direct acting antivirals (DAAs) have demonstrated high cure rates (90-95%) across all
genotypes in less than 12 weeks of all-oral treatment. These highly effective therapeutics offer a path toward
ending the HCV epidemic as drugs become more affordable and global health efforts prioritize expanded access.
The rollout of DAAs relies on diagnostic testing to identify HCV cases and rapidly link eligible patients to treatment
options. In most clinical settings, current HCV testing protocols use a rapid antibody test to diagnose past or
current cases of HCV. While rapid HCV antibody tests are easy to use and widely available, current HCV nucleic
acid amplification tests (NAATs) require venipuncture blood samples and central laboratories where tests are
run by trained technicians on complex, expensive equipment, causing delayed test results and loss to follow-up.
Recent initiatives by the Whitehouse White House’s HCV Elimination Program, WHO, MSF Access Campaign,
and NIH (NOSI: NOT-AI-23-001) have encouraged the development of point-of-care (POC) HCV NAATs to
provide accessible and rapid diagnosis of chronic HCV and aid in the rollout of DAAs. Decentralized, clinic-based
HCV NAATs offer a streamlined approach to patient care where a single test may be used to diagnose HCV,
identify active viremia, and later confirm a cure. There is an abundance of commercial POC NAAT tests for
respiratory diseases, such as influenza or SARS-COV-2, but due to the significant technical challenges of
detecting low viral titers in blood samples, there are no available capillary whole blood rapid POC NAATs for
HCV that meet target product profiles. We have developed a new approach for an integrated POC NAAT for
detecting HCV from whole blood. Our proposed HCV test is a significant departure from most existing POC tests
that use classical extraction methods (solid phase extraction), multiple buffer exchanges, reaction chambers,
PCR amplification, and robotics for physical actuation to automate and miniaturize laboratory-based PCR
workflows. Here, we propose an innovative paper-based device with novel whole blood sample preparation and
electrophoretically-mediated RNA purification, amplification, that is capable of simultaneously extracting and
amplifying viral HCV RNA from whole capillary blood using reverse transcription recombinase polymerase
amplification. The test cartridge consists of a paper and plastic device with no moving parts and provides results
in less than 30 minutes. This low complexity diagnostic t...

## Key facts

- **NIH application ID:** 10995071
- **Project number:** 1R01AI180936-01A1
- **Recipient organization:** UNIVERSITY OF WASHINGTON
- **Principal Investigator:** Jonathan D Posner
- **Activity code:** R01 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2024
- **Award amount:** $776,510
- **Award type:** 1
- **Project period:** 2024-07-03 → 2029-05-31

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10995071

## Citation

> US National Institutes of Health, RePORTER application 10995071, Point-of-care Nucleic Acid Amplification Test for pangenomic Hepatitis C diagnosis in outpatient clinics (1R01AI180936-01A1). Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/grant/nih/10995071. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*